Bioventus Names David Varner Vice President of Marketing, Active Healing Therapies

DURHAM, N.C.–(BUSINESS WIRE)–Bioventus, a global leader in orthobiologic solutions, today announced it has named David Varner as Vice President of Marketing, Active Healing Therapies (AHT). Varner will be responsible for developing and executing global strategic marketing plans for the AHT business. He will also provide leadership to its sales training, marketing intelligence, marketing, external communications and professional affairs & medical education business functions.

“We are very pleased David is joining us to lead global marketing for our Active Healing Therapies business,” said John Nosenzo, Chief Commercial Officer, Bioventus. “His deep experience in healthcare sales, marketing and operations roles combined with his ability to create high performing teams and launch new initiatives will help Bioventus continue to develop our AHT product portfolio and accelerate our growth in orthobiologics around the world.”

Varner joins Bioventus from Beckman Coulter Diagnostics, where he served as Vice President, Global Sales Operations. Previously he worked in the Life Sciences Division of GE Healthcare in a succession of marketing and sales leadership positions, last serving as the company’s General Manager, Global Marketing Operations. Prior to that, Varner spent 13 years in a variety of sales, marketing and operations roles with Siemens Medical Diagnostics (formerly Bayer Diagnostics).

Varner earned a Bachelor of Arts from The College of William and Mary.

About Bioventus

Bioventus is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The company has two product portfolios for orthobiologics, Bioventus Active Healing Therapies and Bioventus Surgical that make it a global leader in active orthopaedic healing. Its EXOGEN Ultrasound Bone Healing System uses safe, effective low intensity pulsed ultrasound (LIPUS) to stimulate the body’s natural healing process. EXOGEN has been used to treat more than 1 million patients worldwide and numerous regulatory agencies including the FDA, Health Canada, BSi, TGA, Medsafe, UAE Ministry of Health and SFDA have granted their approval of the product. Today it is the leading bone healing system in the market with complaints for lack of efficacy averaging less than 1%.

Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.BioventusGlobal.com and follow the company on Twitter @Bioventusglobal.

Bioventus, the Bioventus logo and EXOGEN are registered trademarks of Bioventus.